Mont-Saint-Guibert (Belgium), December 29, 2022, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the issue of new warrants.
For further information, please contact:
Nyxoah
Jeremy Feffer, VP IR and Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 917 749 1494
Last Trade: | US$6.43 |
Daily Change: | 0.08 1.26 |
Daily Volume: | 80,251 |
Market Cap: | US$240.740M |
August 18, 2025 August 08, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load